Skip to main content
. 2017 May 11;7:1796. doi: 10.1038/s41598-017-01268-4

Figure 2.

Figure 2

Serum Shh and IL-6 significantly differ between normal and cancer patients. (A) Serum and plasma Shh and IL-6 levels from healthy volunteers, early operable and untreated progressive metastatic breast cancer patients. (B) Serum Shh and IL-6 levels from early operable patients before and after surgery, as well as before and after chemotherapy from untreated progressive metastatic patients. (C) ROC curves of serum Shh and IL-6 as predictors in progressive metastatic breast cancer patients.